• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

The EPAD project holds its general assembly meeting in Amsterdam

2018-05-23News

 

This year, the European Prevention of Alzheimer’s Dementia (EPAD) general assembly meeting was held in Amsterdam, under the banner “How to assure sustainability”. It was hosted by VU University Medical Center (VUmc) Amsterdam and kindly sponsored by VUmc, Amgen, Novartis and Janssen. The meeting provided a chance to gather everyone from across many different countries who work on the EPAD project to discuss progress and future activities.

Discussions on study progress and future plans

The general assembly meeting commenced with Serge Van der Geyten, Craig Ritchie, and Philip Scheltens welcoming more than 180 attendees. They gave a general overview of the project, reflected on the evolution of EPAD and introduced the agenda for the coming days. Neil Mitchell, Joe Milne and Kristy Draper then explained the role of the University of Edinburgh (UEDIN) in the EPAD Longitudinal Cohort Study (LCS) and the Proof of Concept (PoC) platform. The enhanced role of IQVIA within the study management under the leadership of UEDIN was also reported. Craig Ritchie closed the day by presenting the LCS and Trial Delivery Centers (TDCs) network as the heart and soul of the EPAD project.

The second day placed the emphasis squarely on the EPAD LCS.
During the first session, Joe Milne reported the current LCS status and the progress thus far. Besides the increased recruitment rate, we were glad to see the EPAD family of TDCs growing –17 sites are now enrolling research participants and a number of other sites should be activated and opened in the coming days and weeks. Katrin Haeverans, Emma Law and Craig Ritchie provided more insights to the implemented LCS recruitment strategies, like the establishment of the LCS recruitment taskforce and activation of PrePAD Velocity for all sites. The latter initiative will not only boost recruitment, but will further enrich the LCS with prodromal Alzheimer’s disease research participants and thus ensure the LCS can serve as a successful readiness cohort for the first PoC appendix.
The next session was hosted by Craig Ritchie, who invited five national principal investigators to present their TDCs and report their lessons learned and future plans. There was also a presentation on the EPAD research access process by Judith Syson and James Bonner. During the afternoon of the second day, participants reflected on WP-specific activities and research in the areas of Alzheimer’s disease and dementia via an interactive poster session which was followed by three work package breakout sessions.

The third and final day of the meeting hosted sessions on the PoC protocol, virtual pipeline and EPAD branding. Craig Ritchie and Serge Van der Geyten closed then the meeting by presenting what the project wants to achieve in 2019 and beyond. There was also an exciting announcement that the inclusion of the first candidate for the PoC will likely happen in Q1 2019.

EPAD research participants at the heart of the EPAD project

We are absolutely delighted that seven EPAD research participants from UK, Spain and the Netherlands were willing to come to the general assembly. During the second day of the meeting, they had the opportunity to meet together within the session organised for the research participant panel. The EPAD participant panel has been established in order to involve the research participants in every aspect of the study, giving them an active voice in the project and helping the collaborators learn from their experiences. Currently, there are three panels running across Europe.

47 young researchers are involved in the EPAD project

The highlight of this year’s General Assembly was the presence of 25 young researchers (fellows) involved in the EPAD project. During the third and final day, the EPAD consortium gathered for an EPAD Academy session, who welcomed oral presentations of nine young researchers. It was also fantastic to hear more about the EPAD Academy aims and activities. During the meeting, four fellows also had the opportunity to present their work in a poster format.

Thank you

The three-day assembly firmly emphasised the importance of collaboration between the different European sites and partners to assure the sustainability of our project. We would like to take this opportunity to thank all Epadistas and those involved in and collaborating with EPAD.

To cap off a successful few days, we reached an exciting milestone just as the general assembly concluded, with the news that we now have 700 screened research participants in the LCS.

 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
EPAD v1500 dataset
New webpage dedicated to EPAD data and samples on the EPAD website
2020-11-18
ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
2020-11-17
New paper investigating the prediction of Alzheimer’s disease biomarker status
2020-11-12
The Alzheimer’s Disease Data Initiative supports EPAD
2020-11-06
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Thanks Aridhia for your partnership to facilitate the latest and final @IMI_EPAD #data release. This contains the data for over 2000 participants of the EPAD Longitudinal Cohort Study. Researchers who are interested to access to this dataset can visit ep-ad.org/erap twitter.com/aridhia/status…

reply retweet favorite
1:25 pm · 2021-01-25
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.